The FDA found hidden ingredients in both Addall products. The company recalled one and refused the other.

What the FDA says is in them

Addall is sold as a focus supplement. You find it at the counter in petrol stations and convenience stores, next to the energy shots, and online through the company's own website. It is marketed to people who want to concentrate.

On 3 April 2026 the US Food and Drug Administration published an advisory telling consumers, retailers and distributors not to eat, sell or distribute two Addall products. The reason was what the agency's own testing found inside them.

The advisory names two products from ZMB Enterprises, LLC of Carlsbad, California.

Orange flavoured Addall XR Shot, a 2 fl oz liquid. The FDA says its analysis found undeclared 1,4-DMAA. The agency also says the product contains phenibut, which it describes as not a lawful dietary supplement ingredient.

Addall XL 30 capsules. The FDA says its analysis found undeclared 1,4-DMAA. The agency also says the capsules contain DMHA, which it likewise describes as not a lawful dietary supplement ingredient.

Undeclared means the ingredient is not on the label. Someone reading the bottle would have no way to know it was there.

The separate enforcement report the FDA later published for the shot, recall number H-1263-2026, lists the contents as 1,4-DMAA, phenylethylamine and phenibut. That record adds phenylethylamine to the two substances named in the April advisory.

What the FDA says those ingredients do

On DMAA and DMHA, the advisory says they can raise blood pressure and cause cardiovascular problems, and it names shortness of breath, chest tightness and heart attack.

On phenibut, the advisory lists neurocognitive effects including poor balance, fatigue, and diminished or lost consciousness. It says addiction may develop after only a few uses, and that stopping can bring withdrawal symptoms. It warns of life threatening complications, particularly at higher doses or when phenibut is combined with other prescribed or illicit substances.

Phenibut is worth pausing on, because it is the reason the company moved at all. It is a drug developed in the Soviet Union and used medically in some countries. It is not approved as a dietary supplement ingredient in the United States.

The gap in the middle of this story

Here is the sequence, as the FDA describes it.

On 6 January 2026 the agency informed ZMB Enterprises of its test results and recommended that the company recall both products.

The company agreed to a voluntary recall of one of them, the Addall XR Shot, because of the phenibut. It said it would stop using phenibut in its products.

It declined to recall the Addall XL capsules.

We searched the FDA's enforcement database on 16 October 2026 for every record mentioning Addall. There is exactly one. It is H-1263-2026, it covers the Addall XR Shot only, it is graded Class I, it was initiated on 3 April 2026, the report was published on 2 September 2026, and its status today is ongoing. The distribution note records that the firm markets its products online through its own website.

There is no enforcement record for Addall XL.

That is the part of this worth understanding. The FDA says a product contains an undeclared stimulant and a substance that is not lawful in a supplement. The agency recommended a recall. The company said no. The FDA's published advisory, which is still the most recent word on the page, says the alert will be updated as more information becomes available. It carries a content date of 3 April 2026 and no later update.

Why a company can say no

Almost every food and supplement recall in the United States is voluntary. The FDA has had mandatory recall authority for most foods since 2011, but it is used rarely, and the normal route is that the agency presents its findings and the company withdraws the product itself.

When a company declines, what the public gets instead is the advisory: a page on the FDA's website telling people not to buy the thing. That page does not take a product off a shelf in a petrol station three states away. It relies on retailers reading it.

This is not a loophole somebody is exploiting in secret. It is how the system is built, and it is visible in the record in this case only because the FDA wrote down that it asked and was refused.

What to do if you have one

The FDA's advice is plain. Stop using the products and throw them away. Retailers and distributors should not sell or distribute them. Anyone who becomes ill after taking one should contact a healthcare provider.

If you have been using a product containing phenibut regularly, the withdrawal risk the FDA names is a reason to raise it with a doctor rather than simply stop and hope for the best. We are not going to tell you how to do that, because it is a medical decision and we are a newspaper.